Naiki Taku

Affiliation and department：

Research field (2)： Pathobiochemistry , Urology

Research keywords (3)：酸化ストレス , ロボット支援下手術 , 泌尿器悪性腫瘍

Research theme for competitive and other funds (22)：

2022 - 2025 MicroRNAに着目した去勢抵抗性前立腺癌の予防法とバイオマーカーの探求
2021 - 2024 去勢抵抗性前立腺癌における細胞間連絡機構を介した進展機序の解明と分子基盤
2020 - 2023 エピゲノム酵素LSD1の新規阻害剤による骨転移の難治性疼痛に対する新規治療開発
2019 - 2022 温度感受性に抗がん剤を放出する磁性ナノ粒子を用いた新規がん温熱化学療法の開発
2018 - 2021 Establishment of a Diagnostic Method for Ureteral Cancer Surgical Risk by Multi-parametric Analysis of Preoperative Images and Minimally Invasive Treatment

2017 - 2020 Basic research for elucidation of growth mechanism of testicular tumor by LSD1 and development of therapeutic method by its inhibitor

2017 - 2020 Prognostic analysis of ADC level in MRI for localized bladder carcinoma patients.

2017 - 2020 Development of gene therapy for invasive bladder cancer focusing on genomic instability

2017 - 2020 Molecular mechanisms for prostate cancer prevention induced by natural flavonoid

2016 - 2019 Impact of insulin resistance on prostate cancer in Japanese men: A prospective cohort study

2016 - 2019 A basic research for novel treatment for castration resistant prostate cancer via LSD1 and autophagy

2016 - 2018 Elucidation of epigenome-mediated proliferation mechanism in bladder cancer and development of therapy with novel inhibitors

2015 - 2018 The role of HMGB2 on prostate cancer progression and castration resistance

2015 - 2018 Basic research for clinical application of new thermal therapy to inject magnetic nano-particles into cancer metastasis via IVR technology

2015 - 2018 Development of new therapies for high-risk superficial and invasive bladder cancer by MCL thermotherapy

2014 - 2017 Establishment of the new strategy targeted to intracellular communication mechanism in castration resistant prostate cancer

2014 - 2016 The androgen receptor regulates Ca2+-activated K+ channels KCa2.2 in Prostate Cancer.

2013 - 2016 Development of the selective hyperthermia for the bone metastasis of prostate cancer using anti RANKL antibody-binding nanoparticles

2013 - 2016 Examination of the growth depression effect of bladder tumor through the multinucleated cell formation by the polyethylene glycol

2012 - 2015 Development of a new therapy for prostate cancer by the fusion of the thermotherapy mediated by magnetic field and the immunotherapy

2012 - 2014 GPX2 overexpression is involved in cell proliferation and prognosis of castration resistant prostate cancer

2010 - 2011 Establishment of new prostate cancer metastatic model with androgen independent growth and identification of new mechanism of androgen-independency

Show all

Papers (288)：

Teruki Isobe, Noriyasu Kawai, Maria Aoki, Toshiharu Morikawa, Masakazu Gonda, Nami Tomiyama, Takashi Nagai, Keitaro Iida, Toshiki Etani, Taku Naiki, et al. Late relapsing testicle cancer identified with isochromosome 12p (i12p) fluorescence in situ hybridization (FISH) analysis. Pathology international. 2024
Keitaro Iida, Taku Naiki, Toshiki Etani, Takashi Nagai, Yosuke Sugiyama, Teruki Isobe, Maria Aoki, Satoshi Nozaki, Yusuke Noda, Nobuhiko Shimizu, et al. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Scientific reports. 2024. 14. 1. 2520-2520
Maria Aoki, Taku Naiki, Aya Naiki-Ito, Toshiharu Morikawa, Nayuka Matsuyama, Koei Torii, Taiki Kato, Tetsuji Maruyama, Shingo Inaguma, Takahiro Yasui. Successful treatment with enfortumab-vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder. IJU Case Reports. 2023
Toshiharu Morikawa, Shoichiro Iwatsuki, Aya Naiki-Ito, Masakazu Gonda, Kazumi Taguchi, Taku Naiki, Shuzo Hamamoto, Atsushi Okada, Takahiro Yasui. Urothelial carcinoma occurring in a defunctionalized bladder after urinary diversion due to the bladder exstrophy-epispadias complex. IJU Case Reports. 2023
Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer medicine. 2023

ｍore...

MISC (117)：

内木拓, 杉山洋介, 森川敏治, 磯部輝紀, 清水伸彦, 野田祐介, 永井隆, 惠谷俊紀, 青木マリア, 権田将一, et al. 転移性尿路上皮癌に対する3次治療施行症例の後方視的解析. 日本泌尿器科学会中部総会プログラム・抄録集. 2023. 73rd
磯部輝紀, 内木拓, 杉山洋介, 清水伸彦, 野田祐介, 永井隆, 惠谷俊紀, 青木マリア, 権田将一, 森川敏治, et al. IO治療導入における転移性尿路上皮癌治療予後の変遷. 日本泌尿器科学会中部総会プログラム・抄録集. 2022. 72nd
内木拓, 内木拓, 内木拓, 杉山洋介, 田崎慶彦, 小松弘和, 惠谷俊紀, 青木マリア, 権田将一, 森川敏治, et al. 当院における前立腺神経内分泌癌の検証. 日本泌尿器科学会中部総会プログラム・抄録集. 2022. 72nd
森川敏治, 内木拓, 内木綾, 三村佳久, 青木マリア, 磯部輝紀, 権田将一, 冨山奈美, 清水伸彦, 野田祐介, et al. 転移巣切除を行った尿路上皮癌症例に関する検討. 日本癌治療学会学術集会(Web). 2022. 60th
青木マリア, 内木拓, 磯部輝紀, 権田将一, 冨山奈美, 清水伸彦, 野田祐介, 永井隆, 惠谷俊紀, 飯田啓太郎, et al. 術前化学療法前後における骨格筋変化量は膀胱全摘症例の予後予測因子である. 日本癌治療学会学術集会(Web). 2022. 60th

ｍore...

Education (2)：

2008 - 2012 Nagoya City University
1997 - 2003 Nagoya City University

Professional career (1)：

医学博士 (名古屋市立大学院)

Work history (3)：

2018/03 - 現在 Nagoya City University Graduate School of Medical Sciences Department of Nephro-Urology
2016/04 - 2018/02 Nagoya City University Graduate School of Medical Sciences Department of Nephro-Urology
2003/04 - 2005/03 名古屋市立大学病院臨床研修医

Awards (6)：

2023/11 - 名古屋市立大学理事長賞臨床部門
2023/10 - Best presentation award in Asian Oncology Society 2023 annual congress
2020/03 - 日本泌尿器科学会 JUA EAU Academic Exchange Program
2015/12 - 前立腺財団研究助成最優秀演題
2013/04 - 日本泌尿器科学会総会第7回ヤングリサーチグラント

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page